Loading...
XSHG
600479
Market cap635mUSD
Jul 17, Last price  
10.91CNY
1D
-0.09%
1Q
9.21%
Jan 2017
-16.97%
IPO
134.62%
Name

ZhuZhou QianJin Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
No data to show
P/E
14.25
P/S
1.20
EPS
0.77
Div Yield, %
3.21%
Shrs. gr., 5y
0.19%
Rev. gr., 5y
2.68%
Revenues
3.80b
-5.66%
604,927,872665,825,902602,686,103679,777,224801,429,486904,270,114979,443,7661,256,527,2711,583,422,7331,972,855,0852,194,240,4702,446,684,0742,864,885,5123,182,743,7923,328,553,9633,525,238,1223,626,966,8083,663,844,6134,026,278,5933,798,485,329
Net income
320m
+5.92%
45,387,75559,863,87871,778,673173,619,322129,892,010130,913,57986,382,77982,821,345120,164,483123,767,862105,092,91092,959,634149,428,673207,758,270255,355,306294,313,213297,071,596302,063,356302,508,846320,405,834
CFO
454m
-38.11%
18,454,15976,501,036120,122,93979,263,36137,204,11773,541,73039,129,91622,578,202197,816,674137,632,243183,342,68867,484,546140,879,318283,466,753383,466,469155,493,890542,373,092485,573,058733,472,924453,932,674
Dividend
Jun 27, 20240.35 CNY/sh

Profile

ZhuZhou QianJin Pharmaceutical Co.,Ltd produces and sells pharmaceutical products in China. The company provides gynecology, pediatrics, beauty, antimicrobial, circulatory, endocrine, specialty, digestive, nervous, and cardiovascular products, as well as traditional Chinese medicines It offers its products in various forms, including tablets, capsules, granules, pills, decoctions, powders, and solution. The company also provides ginger tea; feminine hygiene products; and wine. ZhuZhou QianJin Pharmaceutical Co.,Ltd was founded in 1993 and is headquartered in Zhuzhou, China.
IPO date
Mar 12, 2004
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
3,798,485
-5.66%
4,026,279
9.89%
Cost of revenue
2,832,620
3,382,916
Unusual Expense (Income)
NOPBT
965,866
643,363
NOPBT Margin
25.43%
15.98%
Operating Taxes
65,403
57,550
Tax Rate
6.77%
8.95%
NOPAT
900,463
585,813
Net income
320,406
5.92%
302,509
0.15%
Dividends
(149,539)
(257,884)
Dividend yield
3.29%
6.42%
Proceeds from repurchase of equity
(3,382)
BB yield
0.07%
Debt
Debt current
73,243
79,476
Long-term debt
69,926
77,529
Deferred revenue
38,042
44,441
Other long-term liabilities
45,136
7,094
Net debt
(2,102,344)
(1,574,689)
Cash flow
Cash from operating activities
453,933
733,473
CAPEX
(43,989)
Cash from investing activities
574,468
122,148
Cash from financing activities
(202,003)
FCF
995,305
836,964
Balance
Cash
1,997,900
1,731,693
Long term investments
247,613
Excess cash
2,055,588
1,530,379
Stockholders' equity
2,210,046
2,275,966
Invested Capital
1,111,452
1,389,146
ROIC
72.02%
38.11%
ROCE
30.26%
21.95%
EV
Common stock shares outstanding
422,532
418,507
Price
10.77
12.19%
9.60
-23.51%
Market cap
4,550,667
13.27%
4,017,668
-23.51%
EV
3,085,406
3,043,050
EBITDA
1,069,520
738,963
EV/EBITDA
2.88
4.12
Interest
5,965
2,215
Interest/NOPBT
0.62%
0.34%